LENSAR Inc
LNSR
$5.80 2.84%
Exchange NASDAQ Sector Healthcare Industry Medical Devices
Q3 2024
Reported
Published: Nov 7, 2024

Data: Financial Modeling Prep

Company Status Snapshot

Fast view of the latest quarter outcome for LNSR

Report Date

Nov 7, 2024

Quarter Q3 2024

Revenue

13.54M

YoY: +38.2%

EPS

-0.13

YoY: -156.5%

Market Move

+2.84%

Previous quarter: Q2 2024

Follow this company to get upcoming quarter alerts automatically.

Earnings Highlights

Gross Margin

46.3%

Net Income

-1.50M

YoY: -158.5%

"This is a game of inches, and we're gaining each quarter in the important areas of increasing recurring revenues through procedures and market share gains in footprint."

— Nick Curtis
LNSR
Company LNSR

Swipe to view all report sections

Executive Summary

LENSAR delivered a record-breaking Q3 2024, highlighted by strong system placements and a rapid international ramp. Revenue of $13.54 million rose 38% year over year, fueled by 24 ALLY System placements in the quarter, including 11 outside the United States (EU, Taiwan, and Switzerland). The company ended the quarter with a backlog of 24 systems and a global ALLY installed base exceeding 100 systems, contributing to a trailing-12-month recurring revenue run rate of approximately $38 million, up 22% YoY. Despite top-line strength, profitability remained pressured by SG&A investments and ongoing go-to-market expansion; net income was a $1.50 million loss, while adjusted EBITDA turned positive at $0.43 million. Management signaled continued near-term strength in Q4 (with outside-US demand projected to mirror Q3 activity) and framed a longer-term growth narrative around recurring revenue expansion as new installations reach run-rate and as international clearances broaden the addressable market. The company underscored a “game of inches” mindset—careful sequencing of system placements, surgeon training, and revenue recognition—required to scale reimbursement-based recurring revenues. Investors should monitor quarterly execution of international placements, the ramp of newly installed systems to run-rate procedure volumes, and the evolution of gross margins as mix shifts toward more system sales.

Key Performance Indicators

Revenue
Increasing
13.54M
QoQ: 7.15% | YoY: 38.22%
Gross Profit
Increasing
6.27M
46.28% margin
QoQ: -4.79% | YoY: 28.48%
Operating Income
Increasing
-1.01M
QoQ: 34.69% | YoY: 50.34%
Net Income
Decreasing
-1.50M
QoQ: 83.39% | YoY: -158.49%
EPS
Decreasing
-0.13
QoQ: 83.54% | YoY: -156.52%

Revenue Trend

Margin Analysis

Historical Earnings Comparison

PeriodRevenue ($M)EPS ($)YoY GrowthReport
Q1 2026 13.43 1.56 +6.3% View
Q1 2025 14.16 -2.32 +33.7% View
Q4 2024 16.73 -1.61 +38.2% View
Q3 2024 13.54 -0.13 +38.2% View
Q2 2024 12.64 -0.79 +5.2% View